Vimta Labs Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Mon Apr 20 2026

Vimta Labs (NSE: VIMTALABS) is preparing to announce its Q4 FY26 (January–March 2026) financial results for the period ended March 31, 2026. With the stock trading at Rs 550 — against a 52-week high of Rs 820 and a 1-year return of -16% — the Q4 FY26 results will be a pivotal event for investors monitoring the NABL Labs / Pharma Testing / Food Safety sector.

Analyst consensus estimates for Q4 FY26 stand at Rs 185–210 Cr in revenue and Rs 28–36 Cr in profit after tax, with margin expectations of EBITDA 20–23%. The key growth metric of Revenue +12–15% YoY will be watched alongside FY27 management guidance — which analysts consider the most important output from the Q4 FY26 announcement.

Get free investment predictions and live Q4 result alerts on Univest.

Table of Contents

Vimta Labs Q4 Results 2026 Date

The Vimta Labs Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve the audited consolidated and standalone financial results for the quarter and full year ended March 31, 2026 and consider a final dividend recommendation.

Here is the broader Q4 FY26 earnings calendar for major Indian companies:

Company	Results Date	Key Watch
TCS	Apr 9, 2026	PAT Rs 13,718Cr; dividend Rs 31/share
Wipro	Apr 16, 2026	PAT Rs 3,502Cr; buyback Rs 15,000Cr
Waaree Renewable	Apr 16, 2026	Solar EPC Q4 results declared
HDFC Bank	Apr 18, 2026	NIM recovery; Q4 PAT watch
Yes Bank	Apr 18, 2026	NIM 2.5–2.7%; NPA cleanup progress
Infosys	Apr 23, 2026	FY27 CC revenue guidance — critical
IndusInd Bank	Apr 24, 2026	Derivative restatement resolution
Coal India	Apr 27, 2026	Volume decline + dividend

For the complete Q4 FY26 results calendar and real-time announcements, visit Univest Blogs.

Why This Quarter Matters

Q4 FY26 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Vimta Labs, with a stock return of -16% over the past year, this quarter’s results and FY27 guidance are critical for determining whether the stock can recover or faces continued pressure.

Beyond the headline revenue of Rs 185–210 Cr and PAT of Rs 28–36 Cr, investors will focus on three areas: (1) whether FY27 guidance meets consensus expectations for Revenue +12–15% YoY, (2) whether the EBITDA 20–23% margin is sustainable or under pressure, and (3) the dividend or buyback announcement of Rs 5 per share. A positive surprise on any two of these parameters could drive a meaningful post-results re-rating.

Vimta Labs Q4 FY26 Earnings Estimates

Vimta Labs Q4 FY26 Analyst Estimates — Revenue: Rs 185–210 Cr | PAT: Rs 28–36 Cr | Margin: EBITDA 20–23% | Growth: Revenue +12–15% YoY

Access premium SEBI-registered research on Univest.

Brokerages including MOFSL, YES Securities, and JM Financial project Rs 185–210 Cr in revenue (Q3 actual: Rs 170 Cr) and PAT of Rs 28–36 Cr (Q3 actual: Rs 24 Cr). A beat on revenue combined with margin expansion or positive FY27 guidance would be the most positive scenario for the stock.

Metric	Q3 FY26 Actual	Q4 FY26 Estimate	Key Watch
Revenue	Rs 170 Cr	Rs 185–210 Cr	Sequential trajectory
PAT	Rs 24 Cr	Rs 28–36 Cr	Clean earnings quality
Margin	EBITDA 21%	EBITDA 20–23%	Pricing and cost control
Growth Metric	Q3 base	Revenue +12–15% YoY	Volume / Rate / SSG
Dividend	—	Rs 5 per share	FCF signal

Screen Vimta Labs live fundamentals, FII/DII activity, and analyst upgrades on the Univest Screener.

5 Key Factors That Will Drive Vimta Labs Q4 FY26 Performance

1. NABL Labs / Pharma Testing / Food Safety Sector Demand Momentum

Vimta Labs operates in the NABL Labs / Pharma Testing / Food Safety sector — one of India’s structurally growing spaces with Q4 FY26 seasonal demand tailwinds. Q4 is typically the strongest quarter for most sectors due to year-end government capex acceleration, housing completions, and consumer spending peaks. Analyst consensus projects Rs 185–210 Cr for Q4 FY26 — versus Rs 170 Cr in Q3 — implying strong execution execution is required. Track live fundamentals on Univest Screener.

2. Revenue Growth of Revenue +12–15% YoY

The key volume or rate metric of Revenue +12–15% YoY is the single most important operating variable analysts are tracking for Vimta Labs’s Q4 FY26. A strong performance on this metric validates the structural investment thesis and is expected to drive positive stock price movement on results day. A miss versus consensus would likely trigger downward FY27 estimate revisions.

3. Margin Delivery at EBITDA 20–23%

Q4 FY26 margin expectations of EBITDA 20–23% (versus Q3 actual of EBITDA 21%) reflect the interplay of pricing power, input cost management, and operating leverage. If Vimta Labs can sustain or expand margins while delivering estimated revenue, it would mark a continuation of the profitability improvement story and be positively received by institutional investors.

4. FY27 Guidance — The Single Most Critical Catalyst

The single most consequential output from the Q4 FY26 board meeting will be management’s FY27 guidance — revenue growth bands, margin targets, capex plans, and macro risk commentary. In the current global environment — shaped by US-India tariff negotiations and FII outflows — credible and specific FY27 guidance from Vimta Labs will be valued more than the reported Q4 number. Monitor guidance announcements in real time on Univest.

5. Dividend or Capital Allocation Signal

Vimta Labs is expected to consider Rs 5 per share at the Q4 FY26 board meeting. The dividend quantum signals management’s confidence in free cash flow generation. For investors, dividend per share relative to the current market price of Rs 550 determines yield proposition and is a factor in institutional portfolio sizing decisions.

5 Risks to Watch in Vimta Labs Q4 FY26

1. US Tariff Macro Headwinds

The 26% US reciprocal tariff on Indian goods — announced April 2, 2026 — has created FII outflow pressure across Indian equities. For Vimta Labs, indirect impacts include compresed earnings multiples and institutional de-allocation, even if the company’s own supply chain is not directly affected by the tariff.

2. Results Miss Versus Estimates

If Vimta Labs’s Q4 FY26 results miss analyst estimates of Rs 185–210 Cr in revenue and Rs 28–36 Cr in PAT, the stock could correct sharply. The percentage correction is typically larger than the percentage miss — particularly for stocks that have underperformed in the prior 12 months.

3. FY27 Guidance Disappointment

If management’s FY27 guidance falls below Street expectations — even with an in-line Q4 print — the stock may decline on forward estimate cuts. Management credibility is a function of historical guidance delivery; any slippage from prior guidance creates a double discount on new projections.

4. Competitive Pressure in NABL Labs / Pharma Testing / Food Safety

The NABL Labs / Pharma Testing / Food Safety sector faces intensifying competition from domestic capacity additions and international entrants. Vimta Labs’s ability to maintain pricing power, market share, and customer relationships in this environment is a structural risk factor for FY27 estimates.

5. FII Selling and Liquidity Risk

Global risk-off events can trigger concentrated institutional selling that disconnects stock price from underlying fundamentals. Mid- and small-cap stocks like Vimta Labs are particularly vulnerable to liquidity-driven corrections on results day independent of the reported numbers.

Vimta Labs Share Price and Analyst Ratings

Vimta Labs is trading at Rs 550 as of April 2026, against a 52-week high of Rs 820 and a 52-week low of Rs 460. The 1-year return of -16% reflects the macro headwinds of FY26. Analyst 12-month targets range from Rs 700 to Rs 680, implying potential recovery from current levels contingent on Q4 execution and FY27 guidance delivery.

Brokerage	Rating	12M Target	Investment Thesis
MOFSL	Buy	Rs 680	NABL labs demand strong; pharma testing
JM Financial	Buy	Rs 650	Food safety testing regulatory push
YES Securities	Buy	Rs 700	Revenue +12–15%; margin best-in-class

Download the Univest iOS App or Univest Android App to track Vimta Labs live price, charts, and receive real-time Q4 result alerts from SEBI-registered analysts.

Conclusion

Vimta Labs Q4 FY26 results on May 2026 (Expected) will be a key earnings event for investors monitoring the NABL Labs / Pharma Testing / Food Safety sector. With analyst consensus projecting revenue of Rs 185–210 Cr and PAT of Rs 28–36 Cr, the stock at Rs 550 offers a risk-reward profile that depends on execution and FY27 guidance credibility. For more Q4 FY26 previews across sectors, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions. For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: What is the Vimta Labs Q4 results 2026 date?

The Vimta Labs Q4 FY26 results date is May 2026 (Expected). The board of directors will meet to approve audited Q4 FY26 financial results and consider a final dividend recommendation.

Q: What is the Vimta Labs Q4 FY26 PAT estimate?

Analysts estimate Vimta Labs Q4 FY26 PAT in the range of Rs 28–36 Cr, based on revenue of Rs 185–210 Cr and margin of EBITDA 20–23%. Q3 FY26 actual PAT was Rs 24 Cr.

Q: What is Vimta Labs’s share price ahead of Q4 results?

Vimta Labs is trading at Rs 550 as of April 2026. The 52-week high is Rs 820 and the 52-week low is Rs 460. The 1-year return is -16% and market capitalisation is Rs 1,350 Cr.

Q: Will Vimta Labs declare a dividend in Q4 FY26?

Vimta Labs is expected to consider Rs 5 per share at the Q4 FY26 board meeting. The quantum will be confirmed on the results announcement date.

Q: Which analysts have a Buy rating on Vimta Labs?

MOFSL (target Rs 680), JM Financial (target Rs 650), YES Securities (target Rs 700) hold Buy ratings. Consult a SEBI-registered financial advisor before investing.

Q: What were Vimta Labs Q3 FY26 results?

Vimta Labs reported Q3 FY26 (October–December 2025) revenue of Rs 170 Cr and PAT of Rs 24 Cr, with margin at EBITDA 21%. Q3 actuals form the sequential base against which Q4 FY26 estimates are benchmarked.

Q: When do Infosys and TCS announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026 — PAT Rs 13,718 crore and revenue Rs 70,698 crore, with a Rs 31/share final dividend. Full preview at https://univest.in/blogs/tcs-q4-results-2026-date-preview. Infosys Q4 FY26 results are scheduled for April 23, 2026 — FY27 CC revenue guidance is the critical watch. Full preview at https://univest.in/blogs/infosys-q4-results-2026-date-preview.

Q: Is Vimta Labs a good investment ahead of Q4 results?

This depends on your risk appetite, investment horizon, and portfolio context. Vimta Labs has compelling factors — NABL labs demand strong; pharma testing — alongside genuine near-term risks including US tariff macro headwinds and FY27 guidance uncertainty. Analyst consensus targets range from Rs 700 to Rs 680. Consult a SEBI-registered financial advisor before investing.